@article{oai:repo.qst.go.jp:00047210,
 author = {Takano, Harumasa and Arakawa, Ryosuke and Nogami, Tsuyoshi and Suzuki, Masayuki and Nagashima, Tomohisa and Fujiwara, Hironobu and Kimura, Yasuyuki and Kodaka, Fumitoshi and Takahata, Keisuke and Shimada, Hitoshi and Murakami, Yoshitaka and Tateno, Amane and Yamada, Makiko and Ito, Hiroshi and Kawamura, Kazunori and Zhang, Ming-Rong and Takahashi, Hidehiko and Kato, Motoichiro and Okubo, Yoshiro and Suhara, Tetsuya and 高野 晴成 and 荒川 亮介 and 野上 毅 and 鈴木 雅之 and 永嶌 朋久 and 藤原 広臨 and 木村 泰之 and 小高 文聰 and 高畑 圭輔 and 島田 斉 and 村上 義孝 and 舘野 周 and 山田 真希子 and 伊藤 浩 and 河村 和紀 and 張 明栄 and 高橋 英彦 and 加藤 元一郎 and 大久保 善朗 and 須原 哲也},
 issue = {4},
 journal = {The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)},
 month = {Dec},
 note = {Norepinephrine transporter (NET) plays important roles in the treatment of various neuropsychiatric disorders, such as depression and attention deficit hyperactivity disorder (ADHD). Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression. Previous positron emission tomography (PET) studies have reported over 80% serotonin transporter occupancy with clinical doses of selective serotonin reuptake inhibitors (SSRIs), but there has been no report of NET occupancy in patients treated with relatively NET-selective antidepressants. In the present study, we used PET and (S,S)-[18F]FMeNER-D2 to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment. Reference data for the calculation of occupancy were derived from age-matched healthy controls. The result showed approximately 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline. The estimated effective dose (ED50) and concentration (EC50) required to induce 50% occupancy was 65.9 mg/d and 79.8 ng/ml, respectively. Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.},
 pages = {553--560},
 title = {Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2.},
 volume = {17},
 year = {2013}
}